CARMEL, INDIANA, April 1, 2002 — GENI announced today that the patent infringement suit filed by Sabinsa has been settled. Terms of the settlement were not disclosed.
GENI’s decision to settle was solely based on economic considerations, not due to the merits of the case. Mr. Ajay Patel, President & CEO of GENI commented, "The integrity of proprietary information is a concern within our industry. GENI is equally committed to protecting its intellectual property."
Currently, GENI is investing heavily into clinical research associated with their Ayurvedic extracts. They recently extended their Boswellia Serrata study for an additional nine months in order to provide significant clinical evidence regarding the efficacy of their product.
GENI supplies the natural products industry with the finest quality Ayurvedic herbal extracts, Standardized extracts, Mineral yeasts, Nutraceuticals, and Kosher certified products.